Found: 6
Select item for more details and to access through your institution.
BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer.
- Published in:
- Journal of Cellular Biochemistry, 2007, v. 102, n. 5, p. 1171, doi. 10.1002/jcb.21343
- By:
- Publication type:
- Article
Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes.
- Published in:
- Journal of Surgical Oncology, 1991, v. 46, n. 1, p. 31, doi. 10.1002/jso.2930460108
- By:
- Publication type:
- Article
Targeting BCL-2 overexpression in various human malignancies through NF-?B inhibition by the proteasome inhibitor bortezomib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 56, n. 1, p. 46, doi. 10.1007/s00280-004-0944-5
- By:
- Publication type:
- Article
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 54, n. 4, p. 343, doi. 10.1007/s00280-004-0811-4
- By:
- Publication type:
- Article
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2014, v. 33, n. 1, p. 29, doi. 10.1186/s13046-014-0102-9
- By:
- Publication type:
- Article
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
- Published in:
- International Journal of Cancer, 2008, v. 123, n. 8, p. 1950, doi. 10.1002/ijc.23723
- By:
- Publication type:
- Article